Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
The Pharma Letter8h
Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO
Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.
Pharmabiz17h
Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer
Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...
Daily17h
Roche bags USFDA nod for companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...
Trump tariffs on chips and drugs would hit US allies in Asia
US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to ...
Malaysia Sun20h
US allies in Asia would suffer with Trump tariffs on chips, drugs
U.S. President Donald Trump announced plans to impose tariffs on imported computer chips, pharmaceuticals, and steel, aiming to drive more manufacturing within the United States ...